Skip to main content

Annick Desjardins

Professor of Neurosurgery
Neurosurgery, Neuro-Oncology
Duke Box 3624, Durham, NC 27710
the Preston Robert Tisch Brain, Rm. 047 Baker House, DUMC 3624, Durham, NC 27710

Selected Grants


Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas

ResearchCo Investigator · Awarded by National Institutes of Health · 2015 - 2022

Establishing a Rationale for PVSRIPO Immunotherapy in Newly Diagnosed GBM

ResearchInvestigator · Awarded by National Brain Tumor Society · 2019 - 2022

Phase 2 study of SYM004 for adult patients with recurrent glioblastoma

Clinical TrialPrincipal Investigator · Awarded by Symphogen A/S · 2015 - 2021

Phase 1 Multicenter, Open-Label, Dose-Escalation, Combination Study of Marizomib and Bevacizumab-Naive Subjects with Grade IV Malignant Glioma

Clinical TrialPrincipal Investigator · Awarded by Celgene Research and Development · 2015 - 2021

A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06840003 in Patients with Malignant Glioma

Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2016 - 2020

Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma. MRZ112

Clinical TrialPrincipal Investigator · Awarded by Triphase Research and Development Corp · 2016 - 2020

Development of a Therapeutic for Brain Tumor Immunotherapy

ResearchInvestigator · Awarded by National Institutes of Health · 2018 - 2019

Combining PVSRIPO Immunotherapy with Lomustine for the Treatment of Recurrent GBM

ResearchCo-Principal Investigator · Awarded by National Brain Tumor Society · 2017 - 2019

A Phase 1 Study of PTC in Patients with Advanced Solid Tumors

ResearchPrincipal Investigator · Awarded by PTC Therapeutics, Inc · 2016 - 2017

External Relationships


  • Biodexa
  • Chimerix, Inc.
  • Istari Oncology
  • Orbus Therapeutics, Inc.

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.